SARS-CoV-2 Archives | Mikhail Blagosklonny Oncotarget

“These findings underscore the need for rigorous epidemiologic, longitudinal, clinical, histopathological, forensic, and mechanistic studies to assess whether and under what conditions COVID-19 vaccination or infection may be linked with cancer.“

A growing number of post-pandemic reports have described cancer diagnoses, recurrence, or progression following COVID-19 vaccination or SARS-CoV-2 infection. While no causal relationship has been established, these observations raise important questions that warrant careful, hypothesis-driven investigation.

The rapid development and global distribution of mRNA and viral vector vaccines during the pandemic was a landmark achievement in public health, essential in reducing severe COVID-19 cases and mortality. However, the novelty of these vaccines and the absence of long-term carcinogenicity or genotoxicity testing have led some researchers to ask whether rare but biologically plausible interactions with cancer pathways might exist.

At the same time, pandemic-related disruptions in routine cancer screening and treatment were anticipated to influence diagnosis patterns. Yet, some reports have described unexpected phenomena, such as rapid disease progression in previously stable cancers or tumor appearance near injection sites, that are not easily explained by delayed care alone.

The Review: Examining 69 Studies on Cancer Diagnoses After COVID-19 Vaccination or Infection

In a review published in Volume 17 of Oncotarget, titled “COVID vaccination and post-infection cancer signals: Evaluating patterns and potential biological mechanisms,” Charlotte Kuperwasser (Tufts University) and Oncotarget Editor-in-Chief Wafik S. El-Deiry (The Warren Alpert Medical School of Brown University) examined 69 peer-reviewed publications spanning January 2020 to October 2025.

The review included 66 article reports representing more than 300 individual patients from 27 countries, as well as two retrospective population-level studies (from Italy and South Korea) and one longitudinal analysis of 1.3 million U.S. military personnel. These studies collectively examined cancer diagnoses, recurrences, or unusually rapid disease progression following COVID-19 vaccination or SARS-CoV-2 infection.

Rather than stating causation or quantifying risk, the review aimed to identify recurring clinical patterns and explore plausible biological mechanisms. The authors emphasize that their findings should be viewed as hypothesis-generating, reflecting an early phase of signal detection.

The Findings: Key Clinical Patterns Observed Across Cancer Case Reports and Population Studies

Most reports reviewed (81%) were single-patient case studies or small series. Hematologic malignancies, including non-Hodgkin lymphoma, cutaneous T-cell lymphoma, and leukemia, were most frequently described. Reports also included solid tumors such as breast cancer, glioblastoma, pancreatic cancer, melanoma, and sarcoma.

In several cases, patients experienced tumor recurrence or rapid disease progression shortly after vaccination, including individuals previously in remission. A subset of cases described tumor development at or near the injection site or in regional lymph nodes.

The two population-based studies found modest associations between vaccination and increased incidence of certain cancers, including thyroid, breast, lung, and colorectal cancer. However, both studies acknowledged limitations such as short follow-up periods, potential detection bias, and confounding factors related to healthcare access.

The Hypotheses: Exploring Biological Mechanisms Linking COVID-19 Vaccination or Infection to Cancer Activation

The core insight of the review was not a determination of causality, but the recognition of rare, temporally associated patterns that deserve further investigation. One proposed mechanism involves temporary immune dysregulation following vaccination or infection. Elevated levels of cytokines such as IL-6, TNF-α, and IL-1β, well-documented after mRNA vaccination, may impair immune surveillance, allowing latent tumors to emerge or existing disease to accelerate.

Another hypothesis focuses on the SARS-CoV-2 spike protein, which may persist in certain tissues longer than initially expected. In some studies, spike protein expression was identified in tumor samples, prompting questions about its potential effects on tumor behavior or microenvironmental signaling.

The review also discusses residual plasmid DNA fragments that may be present from the mRNA vaccine manufacturing process. While no evidence currently supports genomic integration in humans, the potential for host cell uptake and biological impact remains a theoretical concern.

These mechanisms are contextualized within broader literature on how viral infections and inflammation can affect cancer initiation and progression. As the authors note, “Establishing causality between SARS-CoV-2 infection, COVID-19 vaccination, and cancer requires a level of evidence far beyond temporal association.”

The Impact: Implications for Cancer Surveillance and Vaccine Safety Research

If any association between COVID-19 vaccination or infection and cancer exists, it is likely rare and limited to specific contexts such as individuals with immune dysregulation, latent oncogenic viral infections, or undiagnosed malignancies. Nonetheless, identifying and understanding these interactions is essential for refining vaccine safety profiles and informing long-term public health strategies.

Importantly, the review does not challenge the value of COVID-19 vaccination. Rather, it calls for deeper investigation of how immune stimulation, especially when repeated over time, may intersect with cancer biology in certain individuals.

Future Perspectives and Conclusion

The authors conclude with a call for more rigorous, multidisciplinary research. Future studies should include prospective epidemiological monitoring, histopathologic tissue analysis, immune profiling, and molecular tracking of spike protein or vaccine-derived elements.

Crucially, these questions can only be answered through well-designed, transparent investigations, not assumptions. While the evidence today does not justify changing clinical practice, it does suggest that the interface between immune stimulation and tumor biology is more complex than previously understood.

As the pandemic passes, there is an opportunity to conduct systematic research into these observations using established scientific methods and long-term surveillance frameworks.

Click here to read the entire review published by Oncotarget.

_______

Oncotarget is an open-access, peer-reviewed journal that has published primarily oncology-focused research papers since 2010. These papers are available to readers (at no cost and free of subscription barriers) in a continuous publishing format at Oncotarget.com.

Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science).

Click here to subscribe to Oncotarget publication updates.

For media inquiries, please contact media@impactjournals.com.

In this new study, researchers investigated the interplay between the SARS-CoV-2 spike protein and tumor suppressor gene p53.

—

The profound impact of the COVID-19 pandemic, caused by the SARS-CoV-2 virus, has been felt across various domains, including the realm of cancer research and treatment. As scientists delve deeper into the intricate mechanisms of this viral pathogen, intriguing revelations have emerged regarding its potential influence on cellular processes pivotal to cancer development and progression.

In a new study, researchers Wafik S. El-Deiry and Shengliang Zhang from Brown University and Lifespan Health System shed light on the intricate interplay between the SARS-CoV-2 spike protein and the tumor suppressor p53, a key guardian of genomic integrity. On May 3, 2024, they published their new research paper in Oncotarget’s Volume 15, entitled, “Transfected SARS-CoV-2 spike DNA for mammalian cell expression inhibits p53 activation of p21(WAF1), TRAIL Death Receptor DR5 and MDM2 proteins in cancer cells and increases cancer cell viability after chemotherapy exposure.”

The Study

In this study, researchers El-Deiry and Zhang uncovered a hitherto unknown facet of the SARS-CoV-2 spike protein’s impact on cancer cells. Their findings, meticulously detailed in their research paper, have ignited a newfound curiosity within the scientific community.

To appreciate the significance of this discovery, one must first comprehend the critical function of the p53 protein, often referred to as the “guardian of the genome.” This multifaceted tumor suppressor plays a pivotal role in safeguarding cellular integrity by regulating various processes, including cell cycle arrest, DNA repair, and apoptosis (programmed cell death). When cells encounter stress or DNA damage, p53 is activated, triggering a cascade of events aimed at preserving genomic stability or eliminating compromised cells.

The study has unveiled a remarkable phenomenon: the SARS-CoV-2 spike protein appears to disrupt the intricate balance of the p53 pathway, potentially compromising its tumor-suppressive capabilities. Through a series of meticulously designed experiments, the researchers demonstrated that the presence of the SARS-CoV-2 spike protein in cancer cells interferes with the binding of p53 to its negative regulator, MDM2.

This disruption, in turn, impedes the activation of key downstream targets of p53, including the cell cycle regulator p21(WAF1), the apoptosis-inducing TRAIL Death Receptor DR5, and even MDM2 itself. Consequently, cancer cells expressing the SARS-CoV-2 spike protein exhibited a diminished response to chemotherapeutic agents, manifested by a reduced induction of these critical p53 targets and an increased cell viability following treatment.

Implications for Cancer Therapy

The ramifications of this discovery are far-reaching, particularly in the context of cancer treatment. Chemotherapy remains a cornerstone of cancer management, and its efficacy is heavily reliant on the proper functioning of cellular mechanisms that detect and respond to DNA damage. The p53 pathway plays a pivotal role in this intricate process, acting as a sentinel that triggers cell cycle arrest or apoptosis in response to genotoxic insults.

However, the findings of this study suggest that the presence of the SARS-CoV-2 spike protein may compromise these critical defense mechanisms, potentially rendering cancer cells more resistant to chemotherapeutic agents. This revelation raises concerns about the potential impact of SARS-CoV-2 infection or the administration of spike protein-based vaccines on the efficacy of cancer treatments, particularly in individuals undergoing chemotherapy.

Mechanistic Underpinnings

While the study has shed light on the disruption of the p53 pathway by the SARS-CoV-2 spike protein, the precise mechanisms underlying this phenomenon remain to be fully elucidated. Several intriguing questions arise:

What are the structural determinants that govern the interaction between the SARS-CoV-2 spike protein and components of the p53 pathway?
Could post-translational modifications of the spike protein or p53 itself influence their functional interplay?
How do different cellular contexts, such as varying expression levels of p53 regulators or the presence of specific mutations, modulate the observed effects?
Can this newfound knowledge be leveraged to develop strategies that mitigate the potential impact of SARS-CoV-2 on cancer treatment outcomes?

Addressing these questions will require a concerted effort from the scientific community, involving multidisciplinary collaborations and a diverse array of experimental approaches.

Expanding the Scope of Investigation

While the current study focused on the interaction between the SARS-CoV-2 spike protein and the p53 pathway, it is essential to broaden the scope of investigation to encompass other viral proteins and their potential impact on cellular processes relevant to cancer development and progression. The SARS-CoV-2 genome encodes a multitude of proteins, each with the potential to interact with various host factors and signaling cascades.

Exploring these interactions may unveil additional mechanisms by which SARS-CoV-2 infection could influence tumorigenesis, metastasis, or therapeutic responses. Additionally, investigating the effects of viral proteins on DNA damage sensing, repair mechanisms, and other cellular stress response pathways could yield invaluable insights into the intricate interplay between viral infections and cancer biology.

Implications Beyond COVID-19

The findings of this study have implications that extend beyond the realm of SARS-CoV-2 and COVID-19. They underscore the importance of thoroughly evaluating the potential consequences of viral proteins or antigens employed in vaccine development on critical host pathways, such as those involved in tumor suppression and DNA damage response.

As the scientific community continues to develop novel vaccines and therapeutic interventions, it is imperative to consider the potential impact of these interventions on cellular processes essential for maintaining genomic integrity and preventing malignant transformation. Comprehensive preclinical studies and rigorous safety assessments should be undertaken to ensure that the benefits of these interventions outweigh any potential risks, particularly for individuals with pre-existing conditions or those undergoing cancer treatment.

Collaborative Efforts & Future Directions

Unraveling the complexities of the SARS-CoV-2 spike protein’s interactions with the p53 pathway and other cellular processes will require a concerted effort from researchers across various disciplines. Interdisciplinary collaborations between virologists, cancer biologists, structural biologists, and computational scientists will be crucial in elucidating the mechanistic underpinnings of these interactions and their potential implications for cancer development and treatment.

Furthermore, it is essential to conduct long-term studies to assess the potential long-term consequences of SARS-CoV-2 infection or spike protein exposure on cancer incidence and progression. Such investigations could shed light on the potential risks associated with repeated exposure to viral proteins or antigens, as in the case of booster vaccinations.

A Call for Vigilance & Proactive Measures

The findings of this groundbreaking study serve as a clarion call for increased vigilance and proactive measures within the scientific community. As we continue to navigate the complexities of viral pandemics and develop innovative therapeutic interventions, it is imperative to remain cognizant of the potential unintended consequences on critical cellular pathways, such as those involved in tumor suppression and DNA damage response.

By fostering interdisciplinary collaborations, embracing rigorous scientific inquiry, and maintaining a commitment to thorough preclinical evaluation, we can ensure that our efforts to combat viral threats do not inadvertently compromise our ability to combat cancer and other life-threatening diseases.

The path forward is one of cautious optimism, where scientific discoveries illuminate potential risks while simultaneously paving the way for novel strategies to mitigate these risks and safeguard human health. It is through this delicate balance of exploration and prudence that we can continue to make strides in our fight against both viral and malignant diseases, ensuring a brighter and healthier future for all.

Click here to read the full research paper in Oncotarget.

—